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Abstract Extracellular nucleotides, acting through P2
receptors, can regulate gene expression via intracellular
signaling pathways that control the activity of transcription
factors. Relatively little is known about the activation of
transcription factors by nucleotides in immune cells. The
NF-κB family of transcription factors is critical for many
immune and inflammatory responses. Nucleotides released
from damaged or stressed cells can act alone through
certain P2 receptors to alter NF-κB activity or they can
enhance responses induced by pathogen-associated mole-
cules such as LPS. Nucleotides have also been shown to
regulate the activity of other transcription factors (AP-1,
NFAT, CREB and STAT) in immune and related cell types.
Here, we provide an overview of transcription factors
shown to be activated by nucleotides in immune cells, and
describe what is known about their mechanisms of
activation and potential functions. Furthermore, we propose
areas for future work in this new and expanding field.
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Abbreviations
AP-1 activator protein 1
ATF activating transcription factor
ATPγS adenosine-5′-O-(3-thiotriphosphate)
BzATP 2′3′-O-(4-benzoylbenzoyl)-ATP
CaM kinase Ca
2+/calmodulin-dependent protein
kinase
CBP CREB-binding protein
ChIP chromatin immunoprecipitation
COX-2 cyclooxygenase-2
CRE cyclic AMP-response element
CREB CRE binding protein
EMSA electrophoretic mobility shift assay
ERK extracellular signal-regulated kinase
IκB inhibitor of NF-κB
IL interleukin
iNOS inducible nitric oxide synthase
JAK Janus kinase
LPS lipopolysaccharide
MAP kinase mitogen-activated protein kinase
MEK MAP kinase/ERK kinase
NFAT nuclear factor of activated T-cells
NF-κB nuclear factor κB
RSK2 ribosomal S6 kinase 2
STAT signal transducer and activator
of transcription
TNF-α tumor necrosis factor-α
Introduction
Extracellular stimuli regulate gene expression via intracel-
lular signaling cascades that control the activity of
transcription factors. Nucleotides such as ATP are now
considered essential autocrine/paracrine mediators that
influence cell behavior through activation of P2 receptors.
Release of nucleotides from injured or stressed cells may
serve as ‘danger signals’ to cells of the immune system [1].
In addition, nucleotides acting through P2 receptors often
potentiate responses to other mediators, such as neuro-
transmitters, growth factors or cytokines [2, 3]. P2 receptors
are expressed in many cell types, including cells of the
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receptors: P2X are ligand-gated ion channels permeable to
Na
+,K
+ and in many cases Ca
2+; whereas P2Y are G
protein-coupled receptors [4]. Multiple P2X and P2Y
receptors are often expressed on the same cell type and
couple to diverse signaling pathways.
Gene expression is regulated principally at the level of
initiation of transcription. Mammalian genes consist of a
protein coding sequence, a proximal upstream promoter
(sequence to which basal transcription factors bind) and
distant enhancer and/or silencer elements (sequences to
which inducible transcription factors bind). Basal transcrip-
tion factors are proteins that assemble with RNA polymer-
ase to form an initiation complex. Binding of inducible
transcription factors to their response elements enhances or
sometimes represses formation of this initiation complex. In
addition, gene expression can be regulated indirectly via
interactions among transcription factors. Some transcription
factors recruit chromatin remodeling and modification
proteins such as histone acetylases. Acetylation of histones
weakens the interaction between the nucleosome and DNA
permitting assembly of the initiation complex. Alternately,
recruitment of histone deacetylases leads to transcriptional
repression [5]. The activity of inducible transcription
factors can be regulated by several mechanisms, such as
phosphorylation or dephosphorylation, binding of activat-
ing or inhibitory factors, or de novo synthesis.
Transcription factors play critical roles in the develop-
ment and function of the immune system [reviewed in 6–9].
Although the regulation of transcription factors by nucleo-
tides has been studied in detail in several neuronal and
muscle cell types, relatively little is known about the
responses of immune cells.
1 Here, we review evidence for
the regulation of transcription factors by nucleotides in
immune and related cell types, as summarized in Table 1.
We begin with a discussion of the role of P2 receptors in
the regulation of NF-κB in macrophages and macrophage-
like cell types—perhaps the best understood system. This is
followed by brief descriptions of the regulation of AP-1,
NFAT, ATF/CREB and STATs.
Methods for assessing activation of inducible
transcription factors
Several approaches can be used to detect the activation of
transcription factors. DNA binding can be directly moni-
tored using the electrophoretic mobility shift assay
(EMSA), also known as a gel shift assay. The basis of
EMSA is that protein-DNA complexes migrate more slowly
than free DNA when subjected to nondenaturing gel
electrophoresis. To assess transcription factor activity,
nuclear or whole-cell extracts are combined with labeled
double-stranded DNA sequences containing one or more
specific response elements. Retardation of DNA mobility
indicates binding of protein. Specificity can be confirmed
by including an antibody specific for that transcription
factor, which will either block DNA binding or ‘super-shift’
the complex. Recently, protein-DNA array technology has
been developed that permits profiling of the DNA binding
activities of large numbers of transcription factors in one
assay [21].
The chromatin immunoprecipitation (ChIP) technique
allows analysis of protein-DNA interactions in living cells.
The technique involves in vivo cross-linking of chromatin-
associated proteins to DNA, its fragmentation, immunopre-
cipitation with specific antibodies and analysis of the DNA
sequences obtained. Thus, ChIP permits the characteriza-
tion of protein interactions with chromatin in its native
conformation and reveals the effects of protein-protein
interactions that may alter DNA binding [22]. In contrast,
EMSA assesses the binding of proteins to short fragments
of DNA in vitro. Reporter gene assays are also used to
assess transcription factor activity in living cells. Vectors
are constructed encoding the appropriate response elements
upstream of a gene for an indicator protein, such as β-
galactosidase or luciferase. Constructs are then expressed in
the cell system of interest. Activation of the transcription
factor results in quantifiable changes in the expression of
the indicator protein.
There are also several indirect approaches for monitoring
the activation of inducible transcription factors. These
include: (a) monitoring phosphorylation of transcription
factors by immunoblotting using phospho-specific anti-
bodies; (b) assessment of translocation of factors from the
cytosol to the nucleus using various techniques, such as
immunoblots of cytosolic and nuclear fractions, or in situ
immunolabeling; or (c) quantification of levels of transcrip-
tion factors (for those regulated by de novo synthesis) or
regulatory molecules.
Nuclear factor κB (NF-κB) family
of transcription factors
The transcription factor nuclear factor κB (NF-κB) plays an
important role in many types of immune cells [reviewed in
23, 24]. NF-κB was first identified as a protein that binds to
a specific DNA sequence (κB element) within the enhancer
region of the immunoglobulin κ light chain gene in mature
B cells [25]. NF-κB regulates the expression of a wide
variety of genes that are involved in the regulation of
1 Since preparation of this manuscript, an excellent review has been
published on the regulation of MAP kinases and transcription factors
by P2 receptors in microglial cells [53].
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growth and cell survival. This family of transcription
factors consists of five members in mammals: p65 (RelA),
c-Rel, RelB, NF-κB (p50/p105) and NF-κB2 (p52/p100)
[23]. They all contain an N-terminal DNA binding region
known as the Rel homology domain and bind as homo- or
heterodimers to κB elements. The Rel homology domain is
300 amino acids in length and, in addition to DNA binding,
is responsible for dimerization and interaction with inhib-
itory IκB proteins. Transcriptional activation domains are
found in the C-terminal region of p65, c-Rel, and RelB, and
are important for inducing target gene expression. Due to
lack of these domains, homodimers of p50 and p52 have no
intrinsic ability to drive transcription. Both p50 and p52 are
synthesized as longer precursors—p105 and p100, respec-
tively—which are cleaved by the proteasome [26]. The
other three members of the NF-κB family are synthesized
as mature proteins.
In the classical activation pathway, NF-κB is maintained
as an inactive complex in the cytoplasm when bound to
inhibitory IκB proteins (which include IκBα,I κBβ,I κBε
and IκBγ). Activation of NF-κB involves phosphorylation
of IκBb ya nI κB kinase in response to a variety of stimuli,
such as tumor necrosis factor-α (TNF-α), interleukin-1β
(IL-1β) or lipopolysaccharide (LPS) [23]. Phosphorylation
of IκB is followed by its ubiquitination and degradation,
unmasking a nuclear import signal on NF-κB and hence
permitting its translocation to the nucleus, where it
regulates expression of target genes. In the alternative
pathway for NF-κB activation, an IκB kinase phosphor-
ylates inactive p100, triggering its processing and generat-
ing active p52/RelB heterodimers.
Ferrari and coworkers showed that extracellular ATP led
to the activation of NF-κB in the N9 and N13 murine
microglial cell lines [10]. Activation induced by ATP or
LPS (used as a positive control) was monitored by EMSA
to detect binding activity of total cell extracts to κB-specific
oligonucleotide probes (Fig. 1a). Interestingly, relatively
high concentrations of ATP were required to activate NF-
κB, with maximal effects observed at 3 mM (Fig. 1b),
consistent with involvement of the P2X7 receptor, which
has a relatively low affinity for ATP. In contrast to its
effects on NF-κB, ATP suppressed DNA binding activity of
the transcription factor AP-1 (Fig. 1c), indicating that ATP
has specific effects on different transcription factors.
Involvement of the P2X7 receptor in mediating ATP-
induced activation of NF-κB was supported by the agonist
specificity of the response. Responses were elicited by ATP,
ATPγS or BzATP (a relatively potent P2X7 agonist), but
not by the P2Y receptor agonists ADP or UTP. Moreover,
activation of NF-κB was inhibited by the P2X7 receptor
antagonist, oxidized ATP [10]. However, it is now known
that oxidized ATP is not specific for the P2X7 receptor and
can suppress NF-κB activation in cells lacking the P2X7
receptor [27, 28]. The mechanism through which ATP
causes activation of NF-κB is not clear. However, Ferrari
and coworkers did show that activation was sensitive to
inhibitors of proteasomal degradation and caspase activity.
Furthermore, scavengers of reactive oxygen species were
found to inhibit ATP-induced activation of NF-κB[ 10].
It is well established that many inflammatory cells,
including microglia respond to LPS through activation of
NF-κB. LPS, which was used by Ferrari and coworkers as a
positive control, induced NF-κB activation within 15 min.
In contrast, activation of NF-κB was not observed until 3 h
following stimulation with ATP [10]. This delay suggested
an indirect effect of ATP, perhaps mediated via release of
IL-1β or other cytokines. However, the possible role of
soluble factors such as IL-1β was excluded using a series
of approaches including media transfer experiments. Acti-
vation of NF-κB by LPS and ATP also differed in that LPS
led to formation of the classical p65/p50 heterodimers and
p50 homodimers, whereas ATP induced formation of p65
homodimers. Different NF-κB dimers have distinct actions
Table 1 Regulation of transcription factor activity in immune and related cell types by extracellular nucleotides
Transcription factor Change
a Cell type Agonists Receptor References
NF-κB ↑ Murine microglial cell lines N9 & N13 ATP, ATPγS, BzATP P2X7 [10]
↑ Murine macrophage cell line RAW 264.7 BzATP P2X7 [11]
↑ Rabbit and murine osteoclasts BzATP P2X7 [12]
↑ Rabbit and rat osteoclasts UDP, INS48823 P2Y6 [13]
↑ J774 murine macrophage cell line UTP+LPS P2Y6 [14–16]
↓ Jurkat human T lymphoblastoid cell line ATP P2X7 [17]
AP-1 ↓ Murine microglial cell lines N9 & N13 ATP P2X7 [10]
↑ Jurkat human T lymphoblastoid cell line ATP P2X7 [17]
↑ J774 murine macrophage cell line UTP P2Y6 [14]
NFAT ↑ Murine microglial cell line N9 ATP, BzATP P2X7 [18]
ATF/CREB ↑ Murine microglial cell line BV-2 ATP, 2-chloro-ATP P2Y1 [19]
STATs ↑ Murine mast cells ATP P2X7 [20]
aChange refers to whether transcription factor is activated (↑) or suppressed (↓)
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microglial cells likely has different transcriptional effects
than NF-κB activation by LPS or other established
proinflammatory mediators.
BzATP has also been shown to regulate NF-κB signaling
in the murine macrophage cell line RAW 264.7 [11].
Individually, LPS and BzATP were found to increase NF-
κB DNA binding activity of nuclear extracts (measured
using EMSA), while treatment with both agonists resulted
in cooperative activation of NF-κB. To examine the
mechanism, Aga and coworkers monitored levels of the
NF-κB inhibitory protein IκBα by immunoblot (Fig. 2).
Within 15 min, LPS alone rapidly induced degradation of
IκBα, levels of which returned to normal within 30–
45 min. Concomitant stimulation with BzATP delayed the
reappearance of IκBα, consistent with more sustained NF-
κB activity. The mechanism underlying these effects of
nucleotides was thought to involve cross-talk with the Ras/
MEK/ERK pathway. Although responses were attributed to
P2X7 activation, it is possible that other P2 receptors were
involved, since BzATP can activate a number of P2
receptor subtypes in addition to P2X7 [29]. In bacterial
infections where both LPS and nucleotides are present,
cooperative activation of NF-κB in macrophages may
enhance inflammatory responses.
Recent work has shown direct involvement of the P2X7
receptor in mediating ATP-induced activation of NF-κBi n
osteoclasts. Osteoclasts, the large multinucleated cells
responsible for bone resorption, form by the fusion of
precursors of the monocyte-macrophage lineage [30]. The
essential role of NF-κB in osteoclast development was
discovered in genetically modified mice lacking both the
p50 and p52 subunits of NF-κB, in which osteoclasts failed
to develop, resulting in severe osteopetrosis [31]. Osteo-
clasts are terminally differentiated cells that cannot be
isolated in sufficient numbers or purity to permit assess-
Fig. 1a–c ATP induces NF-κB activation in microglial cell lines.
a The microglial N9 cell line (lanes 1–3) or N13 cell line (lanes 4–6)
were either left untreated (Control) or treated with ATP (3 mM) or LPS
(100 ng/ml) as a positive control. After 3 h, total cell extracts were
prepared and analyzed with an NF-κB-specific oligonucleotide by
EMSA. The NF-κB-DNA complex is indicated by filled arrowheads
in a and b. A faster migrating nonspecific complex is marked by
circles. b Dependence of NF-κB activation on the concentration of
ATP or LPS. N9 cells were treated for 3 h with the indicated
concentrations of ATP or LPS and analyzed by EMSA. c The effect of
ATP and LPS on the DNA-binding activity of AP-1. The same cellular
extracts as in a were analyzed with an AP-1-specific oligonucleotide
by EMSA. The AP-1-DNA complex is indicated by the filled
arrowhead. In contrast to its effects on NF-κB, ATP suppressed the
DNA binding activity of AP-1. Reproduced from [10], with copyright
permission of The Rockefeller University Press
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tional assays such as EMSA. To overcome this limitation,
Korcok and coworkers used immunofluorescence to mon-
itor localization of the p65 subunit of NF-κB, which upon
activation translocates from the cytoplasm to the nucleus
[12]. BzATP was applied to osteoclasts isolated from wild-
type and P2X7 receptor knockout mice. In wild-type
osteoclasts, BzATP increased the proportion of cells with
nuclear localization of NF-κB within 30 min (Fig. 3a,d);
whereas, BzATP had no effect on osteoclasts lacking the
P2X7 receptor (Fig. 3c,e). This finding confirmed the
involvement of P2X7 receptors in mediating the actions of
ATP on NF-κB. Interestingly, in contrast to mouse
osteoclasts, which showed maximal effects 30 min follow-
ing exposure to BzATP, rabbit osteoclasts showed maximal
nuclear localization of NF-κB 3 h after exposure to
nucleotide [12], similar to the delayed response observed
by Ferrari and coworkers in microglial cells [10]. The
reason for these differences in activation kinetics among
cell types and species of origin is not clear. Ferrari and
coworkers found that ATP induced formation of p65
homodimers in microglial cells [10]; whether p65 trans-
located as a homodimer or as heterodimer in osteoclasts
was not investigated [12].
In addition to P2X7, P2Y6 receptors have been
implicated in the activation of NF-κB in osteoclasts and
macrophages. To examine P2Y receptor-mediated activa-
tion of NF-κB in osteoclasts, immunofluorescence was
again used by Korcok and coworkers [13]. Rabbit osteo-
clasts were exposed to various P2Y receptor agonists. UDP,
an agonist at P2Y6 receptors, increased the proportion of
osteoclasts displaying nuclear localization of NF-κB with
maximal effects at 3 h (Fig. 4a,d). Control osteoclasts
showed low levels of nuclear NF-κB for up to 4 h (Fig. 4b).
The extent of NF-κB translocation was dependent on UDP
concentration, with maximal effect observed at 10–100 μM
UDP (Fig. 4e). Lactacystin, a proteasome inhibitor, abolished
the UDP-induced activation of NF-κB. In contrast to its action
on osteoclasts, UDP did not induce NF-κB translocation in
bone marrow stromal cells (Fig. 4c), indicating specificity for
cell type.
In addition to UDP, significant translocation of NF-κB
was induced by INS48823 [13], a selective agonist at the
P2Y6 receptor [32]. In contrast, no response was elicited by
2-methylthio-ADP (P2Y1 receptor agonist), UTP (P2Y2
receptor agonist) or low concentrations of ATP sufficient to
activate multiple P2 receptors including P2Y2 and P2X4,
but not P2X7. Thus, the agonist specificity for NF-κB
activation indicates the involvement of P2Y6, but not other
P2Y receptor subtypes known to be present on osteoclasts.
UDP and INS48823 enhanced survival of osteoclasts in
vitro [13], presumably by inhibiting apoptosis—the pre-
dominant form of cell death for osteoclasts [33]. NF-κB has
been implicated in controlling the survival of a number of
cell types [34], including osteoclasts [35]. In this regard, a
cell-permeable peptide inhibitor of NF-κB was found to
block the effect of P2Y6 activation on osteoclast survival
[13]. Enhancement of osteoclast survival through the P2Y6
receptor is consistent with data from 1321N1 human
astrocytes, in which activation of P2Y6 receptors prevented
TNF-α-induced apoptosis [36].
The predominant P2Y receptor expressed by the J774
murine macrophage cell line has been shown to be P2Y6
[15]. Exposure of these cells to UTP alone, which
presumably leads to activation of P2Y6 receptors, does
not activate NF-κB; however, UTP does potentiate LPS-
induced activation of NF-κB as well as expression of
inducible nitric oxide synthase (iNOS) [14]. In a series of
studies, Chen and coworkers found that UTP increased
LPS-induced phosphorylation and degradation of IκBα,b y
enhancing activation of IκB kinase [16]. Enhancement of
IκB kinase activity appeared to involve several signaling
pathways, including P2Y6-mediated elevation of cytosolic
free Ca
2+ and subsequent activation of Ca
2+/calmodulin-
dependent protein kinase (CaM kinase) [14, 16].
In summary, NF-κB is critical for immune and inflam-
matory responses by regulating the expression of key
cytokines, growth factors and effector enzymes. The NF-
κB pathway is highly conserved among species [37] and
plays crucial roles in the development, activity and survival
of osteoclasts [31, 35, 38]. Nucleotides released from
damaged or stressed cells can alter gene expression on
their own or regulate responses induced by LPS, thus
playing potentially important roles in innate immunity. It
will be of interest to examine whether nucleotide signaling
through P2 receptors modulates NF-κB activation induced
by other inflammatory mediators in addition to LPS.
Fig. 2 Effects of the P2X7 agonist BzATP and LPS on levels of
IκBα in a murine macrophage cell line. RAW 264.7 cells were treated
with LPS (100 ng/ml) or BzATP (250 μM) alone or in combination for
the specified times. IκBα levels were assessed by immunoblot
analysis of whole-cell lysates. Within 15 min, LPS alone rapidly
induced degradation of IκBα, levels of which returned to normal
within 30–45 min. Concomitant stimulation with BzATP delayed the
reappearance of the inhibitory protein IκBα, consistent with enhance-
ment of NF-κB activity. Equivalent protein loading was verified by
reprobing membranes with anti-Grb-2 antibodies. Modified from [11],
with permission of the American Physiological Society
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AP-1 is composed of structurally and functionally related
members of the Jun and Fos protein families. Fos proteins
(Fos, FosB, Fra-1 and Fra-2) heterodimerize with members
of the Jun family, whereas Jun proteins (Jun, JunB, JunD)
can form homodimers as well as heterodimers with Fos
proteins. Some members of the ATF/CREB family of
transcription factors can also participate in AP-1 com-
plexes. With many possible combinations of heterodimers
and homodimers comprising the AP-1 complex, a broad
diversity in gene regulation can be achieved [39, 40].
AP-1 translates extracellular signals in immune and
related cell types into changes in the expression of specific
target genes, which in turn control proliferation, differen-
tiation and apoptosis [39]. AP-1 activity can be regulated
by de novo synthesis of subunits, dimer composition, post-
translational modifications and interactions with other
proteins. Two of the components of AP-1 (Jun and Fos)
were first identified as viral oncoproteins, so their role in
tumorigenesis is also well established.
Budagian and coworkers examined the effects of ATP on
AP-1 activity in the Jurkat human T-lymphoblastoid cell line
[17]. Using immunoblots, they found that expression of Jun
and Fos increased 30–60 min following exposure to ATP.
Effects were observed only at ATP concentrations of 1 mM
or higher, consistent with involvement of the P2X7 receptor.
In keeping with increased expression of Jun and Fos, EMSA
of nuclear extracts indicated that AP-1 DNA binding activity
increased within 60 min following exposure to ATP and
continued to intensify for at least 3 h. Supershift analysis
confirmed that the AP-1 complex contained Jun and Fos.
Surprisingly, ATP transiently suppressed NF-κBD N A
Fig. 3a–e BzATP acts
through P2X7 receptors to
induce nuclear translocation
of NF-κB in murine osteo-
clasts. Osteoclasts isolated
from wild-type (WT) and
P2X7 receptor knockout (KO)
mice were treated with
BzATP (300 μM) or vehicle
for 0–4h .a–c The p65
subunit of NF-κB was visual-
ized by immunofluorescence
(green, left). All nuclei were
stained with TOTO-3 (red,
middle), with superimposed
images of NF-κB and TOTO-
3-stained nuclei at right. a
BzATP-treated WT osteo-
clasts showed nuclear locali-
zation of NF-κB at 30 min
(evident as yellow staining in
aiii). b, c In contrast, vehicle-
treated WT and BzATP-trea-
ted KO osteoclasts showed
cytoplasmic localization of
NF-κB. d WT osteoclasts
treated with BzATP exhibited
a significant increase in nu-
clear translocation of NF-κB
at 30 min compared with time
0( * P<0.05). e In contrast,
KO osteoclasts did not show
a significant change in NF-κB
translocation at any time point
after BzATP treatment. Data
are the percentage of osteo-
clasts with nuclear localiza-
tion of NF-κB. Reproduced
from [12], with permission of
the American Society for
Bone and Mineral Research
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3 h. Thus, ATP has opposite effects in Jurkat cells compared
with its effects in microglial cells, in which ATP activates
NF-κB and suppresses AP-1 [10]. Nevertheless, the effects
of ATP were presumably mediated by P2X7 receptors in
both cell types [10, 17].
In Jurkat cells, the mechanism mediating the effect of ATP
on AP-1 was shown to involve the tyrosine phosphorylation
and activation of p56
lck [17] (a tyrosine kinase essential for
signal transduction through the T-cell receptor [41]). In Jurkat
cells, but not JCaM1 cells (a mutant Jurkat cell line that lacks
p56
lck), ATP activated ERK and Jun N-terminal kinase and
enhanced AP-1 activity, indicating an essential role for p56
lck
in regulating AP-1. It is known that AP-1 stimulates
expression of IL-2 in T lymphocytes [42, 43]. In this regard,
Budagian and coworkers found that ATP stimulated IL-2
expression in Jurkat cells but not in JCaM1 cells, consistent
with a role for AP-1 in mediating this response to ATP.
In addition to examining the effects of UTP on NF-κB
signaling, Chen and coworkers assessed the effects of P2Y6
receptor activation on AP-1 activity in the J774 macro-
phage cell line [14]. Using EMSA, they found that UTP
and LPS each induced AP-1 activation and that their effects
were additive.
Fig. 4a–e The P2Y6 receptor
agonist UDP induces nuclear
translocation of NF-κB in rabbit
osteoclasts. Osteoclasts were
treated with UDP or vehicle.
a–c The p65 subunit of NF-κB
was visualized by immunofluo-
rescence (green, left panels), and
the nuclei were stained with
TOTO-3 (red, middle panels).
Superimposed images of NF-κB
and nuclei are shown at right.
a Osteoclast treated with UDP
(10 μM) showed nuclear locali-
zation of NF-κB at 3 h (evident
as yellow staining in aiii). b, c
Osteoclast treated with vehicle
(Control) and stromal cells trea-
ted with UDP (10 μM) showed
cytoplasmic localization of NF-
κBa t3h .d Osteoclasts were
treated with UDP (10 μM) for
0–4 h. The data are the percen-
tages of osteoclasts with nuclear
localization of NF-κB. Signifi-
cant nuclear translocation of
NF-κB was observed at 3 h
compared with time 0
(*P<0.05). e Rabbit osteoclasts
were treated for 3 h with the
indicated concentrations of
UDP. Significant nuclear trans-
location of NF-κB was observed
at 10–100 μM UDP (*P<0.05).
Reproduced from [13], with
permission of the American
Society for Biochemistry and
Molecular Biology
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likely depends upon the subtypes of P2 receptors involved
as well as cell type. Furthermore, cross-talk with other
signaling pathways and transcription factors likely influen-
ces the ultimate effects of AP-1 activation on gene
expression.
Nuclear factor of activated T-cells (NFAT) family
of transcription factors
NFAT is a family of transcription factors that regulate the
differentiation and activation of a number of immune and
related cell types, including T-cells and osteoclasts [7, 8].
This family of proteins consists of five members (NFAT1-
5), of which four are regulated by calcium signaling [7]. All
NFAT proteins contain a highly conserved Rel-homology
region that confers common DNA-binding specificity. Inac-
tive NFAT is maintained in the cytoplasm in a hyperphos-
phorylated state. Elevation of cytosolic free Ca
2+ stimulates
the phosphatase calcineurin, which in turn dephosphorylates
multiple serine residues, exposing a nuclear localization
signal that permits translocation of NFAT to the nucleus.
Ferrari and coworkers examined the effect of ATP on
NFAT activation in the N9 murine microglial cell line [18].
A high concentration of ATP (3 mM) activated NFAT, as
determined by assaying nuclear extracts using EMSA
(Fig. 5). In contrast to the delayed effect of ATP on
activation of NF-κB in these cells, NFAT activity was
evident within 1 min, reached a maximum after 15 min and
diminished in the following 60 min. As shown previously
for the effects of ATP on NF-κB[ 10], activation of NFAT
was mediated by the P2X7 receptor [18]. This conclusion
was based on agonist specificity, with responses induced by
high concentrations of ATP or BzATP, but not by other
nucleotides. In addition, ATP did not activate NFAT in a
P2X7 receptor-deficient cell clone N9R17, although NFAT
could still be activated in these cells by Ca
2+ ionophore. In
this regard, ATP-induced NFAT activation in N9 cells was
dependent on the presence of extracellular Ca
2+ and was
prevented by the calcineurin inhibitors cyclosporin A and
FK506, consistent with NFAT activation through the
canonical signaling pathway.
Using competition and supershift assays in N9 cells,
Ferrari and coworkers demonstrated that ATP induced
activation of NFAT-1 and NFAT-2, but not NFAT-3 or
NFAT-4 [18]. These findings were confirmed by immuno-
blot analyses of nuclear extracts from cells stimulated with
ATP. The functional role of ATP-induced NFAT activation
in microglial cells is poorly understood; however, it was
proposed that microglial NFAT may play a role in inducible
expression of cytokines and, thus, mediate proinflammatory
responses to ATP in the central nervous system [18].
Most isoforms of NFAT are activated by Ca
2+ elevation,
and signaling through many P2X and P2Y receptors
involves Ca
2+ increase (by influx or release from stores,
respectively). Thus, future studies may reveal NFAT to be
downstream of many P2 receptors. The versatility of NFAT
as a regulator of gene expression is thought to be due to
different binding partners within the nucleus. Thus, the
effects of extracellular nucleotides on the activation of
NFAT and its various binding partners will be an important
area for future research.
Activating transcription factor (ATF)/cyclic AMP
response element binding protein (CREB) family
of transcription factors
The ATF/CREB family plays important roles in the regu-
lation of a number of cell functions, including proliferation
and apoptosis. Members of the ATF/CREB family dimerize
with themselves or other family members and bind to the
cyclic AMP response element (CRE) on target genes.
Activation of CREB involves phosphorylation of a single
serine residue (Ser
133), which in turn promotes association
of CREB with the coactivator CREB-binding protein
(CBP), resulting in transcriptional activation [44]. CREB
can be activated by multiple kinases, including: protein
kinase A, regulated by cyclic AMP; CaM kinase, regulated
by cytosolic Ca
2+; and ribosomal S6 kinase 2 (RSK2),
regulated by MAP kinase pathways [45, 46]. CREB
controls the expression of a number of genes, including
members of the AP-1 family of transcription factors.
Brautigam and coworkers have examined signaling
pathways activated by extracellular nucleotides in the BV-
2 murine microglial cell line [19]. LPS induces expression
of iNOS and COX-2 in these cells, a process that was
inhibited by ATP and 2-chloro-ATP (P2Y1 agonist). ATP
also suppressed LPS-induced NO production in this micro-
glial cell line, an effect that was reversed by SB 203580, an
inhibitor of p38 MAP kinase. CREB activation was
assessed indirectly by monitoring Ser
133CREB phosphory-
lation by immunoblot of whole-cell lysates (Fig. 6). Both
ATP (500 μM) and 2-chloro-ATP (10 μM) rapidly induced
phosphorylation of CREB and ATF-1 (phosphorylated
ATF-1 was also recognized by the antibody used to detect
phosphorylated CREB). SB 203580 inhibited ATP-induced
phosphorylation of CREB and ATF-1, implicating p38
MAP kinase in their activation. The potential role of CREB
in the suppression of iNOS and COX-2 expression is not
immediately obvious [47]; however, one possibility con-
sidered by Brautigam and coworkers is that activation of
CREB sequesters the transcriptional coactivator CBP,
preventing its interaction with p65 and thereby inhibiting
the expression NF-κB-dependent genes such as iNOS [19].
66 Purinergic Signalling (2007) 3:59–69Thus, Brautigam and coworkers found that activation of
P2Y1 and possibly other P2 receptors suppresses LPS-
induced expression of iNOS and COX-2 in a microglial cell
line [19]. This is in contrast to the findings of Chen and
coworkers that P2Y6 receptors potentiate LPS-induced
expression of these inflammatory genes in murine J774
macrophages [14, 15]. Further studies of the effects of
nucleotides on CREB activation may be informative. In T
lymphocytes, engagement of the T-cell receptor leads to
phosphorylation of CREB on Ser
133 by a pathway that
involves activation of p56
lck, protein kinase C, Ras, Raf-1,
MEK and RSK2 [45]. Since ATP has been shown to
activate p56
lck in Jurkat cells [17], future studies should
examine the possibility that ATP also induces activation of
CREB in these cells.
Signal transducer and activator of transcription
(STAT) family
The Janus kinase (JAK)/STAT pathway transduces signals
from cytokines, growth factors or cellular stress to regulate
a number of processes including proliferation, differentia-
tion, cell migration and apoptosis [48]. Binding of a
cytokine or growth factor induces dimerization of its
receptor. JAK tyrosine kinases are then recruited to these
dimerized receptor complexes. JAKs are activated by
transphosphorylation and subsequently phosphorylate and
activate STATs (latent transcription factors that reside in the
cytoplasm until activated). There are seven mammalian
STATs that, upon phosphorylation, dimerize and enter the
nucleus, where they bind specific regulatory sequences to
activate or repress the transcription of target genes [49].
Bulanova and coworkers have recently reported the
responses to extracellular ATP of murine bone marrow-
derived mast cells and two mast cell lines, MC/9 and P815
[20]. These cells express multiple subtypes of P2X and P2Y
receptors. Apoptosis of these cells was induced by ATP (1–
3m M) or BzATP (100 μM), consistent with involvement of
the P2X7 receptor. In addition, immunoblotting of whole-cell
lysates with phospho-specific antibodies established that
ATP (3 mM) induced phosphorylation of STAT6 and weak
phosphorylation of JAK2. These effects were rapid and
transient with maximal phosphorylation evident 15 min
following exposure to ATP. In contrast, there was no
apparent change in the other members of the JAK family
(JAK1, JAK3, Tyk2) or in STAT1, STAT3 or STAT5,
indicating specificity of activation. ATP-induced phosphory-
lation of JAK2 and STAT6 was abolished by the P2X7
antagonists KN-62 or oxidized ATP. However, due to lack of
specificity of these antagonists, it is difficult to interpret these
findings. First, although KN-62 is a potent antagonist of the
human and mouse P2X7 receptor [50], it is also an inhibitor
of CaM kinase II [51]. Second, as mentioned above,
oxidized ATP is not a specific P2X7 antagonist [27, 28].
Additional findings of Bulanova and coworkers show
that high concentrations of ATP or BzATP enhance the
production of several cytokines in mast cells including IL-6
and IL-13, which are known to signal through the JAK/
STAT pathway. Therefore, ATP may stimulate the rapid
activation and release of cytokines or other signaling
molecules that bind to receptors on mast cells in an
autocrine fashion to activate JAK/STAT signaling.
Fig. 6 ATP induces phosphorylation of ATF-1 and CREB in a
microglial cell line. BV-2 cells were treated with ATP (500 μM) or the
P2Y1 agonist 2-chloro-ATP (2-Cl-ATP, 10 μM) for 5–15 min. Immuno-
blot analysis of whole-cell lysates revealed levels of Ser
133CREB
phosphorylation (pCREB), an indicator of CREB activation. The
antiSer
133CREB antibody cross-reacted with phosphorylated ATF-1
(pATF-1). Both ATP and 2-chloro-ATP rapidly induced phosphoryla-
tion of CREB and ATF-1. Grb-2 levels are shown in the lower panel as
loading controls. Modified from [19], with permission of Elsevier
Fig. 5 Kinetics of ATP-induced NFAT and NF-κB activation in a
microglial cell line. N9 cells were stimulated for the indicated times
with ATP (3 mM) and nuclear extracts were analyzed by EMSA. Filled
arrowheads indicate positions of the NFAT and NF-κBD N A
complexes. Faster-migrating nonspecific complexes are indicated by
circles. NFAT activity was evident within 1 min following exposure to
ATP, reached a maximum after 15 min and diminished following
60 min. In contrast, NF-κB activation was relatively delayed and
sustained. Reproduced from [18], with permission of the American
Society for Biochemistry and Molecular Biology
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Evidence is accumulating that specific P2 receptors are
involved in the regulation of proliferation, differentiation,
activity and survival of immune and related cell types
through the activation of distinct transcription factors. The
lack of selective agonists and antagonists for many
subtypes of P2 receptors has made it difficult to assess
their specific roles. Development of genetically modified
mouse models (in which receptor subtypes are over-
expressed or deleted) will provide critical information on
the transcriptional effects of specific subtypes of P2
receptors. Such information will be instrumental in deter-
mining the roles of these receptors in inflammation and
immunity, as well as related processes such as osteoclastic
bone resorption [52]. This knowledge may lead to the
identification of P2 receptors or components of their
downstream signaling pathways as targets for therapeutic
intervention in inflammatory and immune disorders.
Leukocytes express multiple subtypes of P2X and P2Y
receptors that play diverse roles in regulating the develop-
ment of the immune system and in modulating inflamma-
tory and immune responses. Although great progress has
been made in sorting out many of the initial signaling
events triggered by activation of P2 receptors, relatively
little is understood about their role in transcriptional regula-
tion. Given the availability of high throughput transcription
factor arrays, ChIP and reporter assay screens, rapid prog-
ress in this field is expected. An important question to be
answered is whether the effects of nucleotides on transcrip-
tion factor activation are direct—mediated through P2
receptors—or indirect—mediated by autocrine/paracrine fac-
tors whose release is stimulated by P2 receptor activation.
Further studies are clearly needed to elucidate the effects
of nucleotides on the transcriptional machinery of various
immune cell types, and interactions with pathways activat-
ed by cytokines, growth factors, extracellular matrix and
other stimuli. The transcriptional effects of nucleotides will
undoubtedly depend on the nature of the stimulus, P2
receptor expression, cell type and cellular environment.
Therefore, the actions of nucleotides on processes such as
proliferation and differentiation must eventually be consid-
ered within the context of a complex dynamic network of
signaling pathways that are activated in spatially and
temporally distinct patterns.
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